Adapta With MVP Pacing System
Adapta® with MVP™ Pacing System offers managed ventricular pacing, atrial therapy, ventricular capture, and remote cardiac telemetry.
Why Is It Critical to Pace Less?
Reducing unnecessary ventricular pacing has been shown to improve clinical outcomes by reducing the risks of atrial fibrillation (AF)1-4 and heart failure hospitalization (HFH).1,4
There is a 1% increase in the risk of AF for each 1% increase in cumulative right ventricular pacing.4
Important Safety Information
Changes in a patient's disease and/or medications may alter the efficacy of a device's programmed parameters or related features.
Risk of Atrial Fibrillation
RV pacing > 40% of the time in DDDR mode was associated with a 2.6-fold increased risk of HFH compared with pacing < 40%.4
Risk of Heart Failure Hospitalization
References
- Anderson HR, Nielsen JC, Thomsen PEB, et al. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997;350:1210-1216.
- Skanes AC, Krahn AD, Yee R, et al, for the CTOPP Investigators. Progression to chronic atrial fibrillation after pacing: The Canadian Trial Of Physiologic Pacing. J Am Coll Cardiol. 2001;38:167-172.
- Neilsen J, Kristensen L, Andersen H, et al. A randomized comparison of atrial and dual chamber pacing in 177 consecutive patients with sick sinus syndrome. J Am Col Cardiol. 2003;42:614-623.
- Sweeney M, Hellkamp A, Ellenbogen K, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-2937.
How the Adapta Pacing System Works
Managed Ventricular Pacing Mode
The new standard of care in pacing is to reduce unnecessary right ventricular pacing to as close to zero as possible. Mounting evidence suggests that right ventricular pacing is associated with a variety of detrimental effects, including risk of heart failure hospitalization and atrial fibrillation.1
Managed Ventricular Pacing
MVP® – Managed Ventricular Pacing provides the following benefits:2
- Promotes intrinsic conduction
- Reduces unnecessary right ventricular pacing by 99%*3
- Provides AAI(R) pacing with ventricular monitoring plus the safety of DDD(R) backup pacing when needed
Completely Automatic – Simple to Use
Atrial Capture Management and Ventricular Capture Management (ACM and VCM):
- Provide complete long-term threshold management automatically
- Ensure pacing outputs remain at safe levels4
TherapyGuide™ – Tailored, Clinically-Oriented Programming Using Physician-Selected Parameters
- Simplifies and tailors programming
- Provides suggested device settings based on physician-selected patient conditions
Quick Look II – All Key Information on One Screen
- Simplifies clinic follow-up with all key information on one screen
- Provides concise overview of patient, device, and lead status
- Routine follow-up measurements are performed automatically
- All measurements are automatic and displayed upon initial interrogation
Detail - Quick Look II on One Screen
Cardiac Compass Trends
Concise information to:
- Identify atrial arrhythmias
- Make key therapy decisions (eg, titrating medications)
- Monitor results of therapy changes
Assess Rhythm Control†
Cardiac Compass® Rhythm Control
† Atrial Arrhythmia Trend of patient who received a change in antiarrhythmic drug therapy during an August follow-up. The change in medical therapy resulted in the decreased incidence and duration of AT/AF.
Assess Rate Control‡
Rate histogram of ventricular beats occurring during exercise-induced AT/AF showing blocked conduction.
Rate histogram of ventricular beats showing good conduction and rate control following change to patient’s pharmacologic therapies for AT/AF.
‡The information collected may help with assessment of rate control and risk for stroke in patients with atrial tachyarrhythmias.
Therapeutic Options for AT/AF
Pacing therapies that may help manage tachyarrhythmias and may alleviate symptoms:
- Atrial Preference Pacing (APP)
- Post Mode Switch Overdrive Pacing (PMOP)
- Conducted AF Response
Therapeutic options for AT/AF
Medtronic CareLink Network for Pacemakers
Medtronic CareLink® Network, the leading Internet-based remote monitoring service, is now available for pacemakers.
* Median number
References
- Sweeney M, Hellkamp A, Ellenbogen K, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-2937. 2. Gillis A, Pürerfellner H, Israel C, et al. Reduction of unnecessary ventricular pacing due to the Managed Ventricular Pacing (MVP) mode in pacemaker patients: Benefit for both sinus node disease(SND) and AV block (AVB) indications. Heart Rhythm. 2005;Abstract AB21-1.
- EnRhythm Device Manual
- Gillis A, Pürerfellner H, Israel C, et al. Reduction of unnecessary ventricular pacing due to the Managed Ventricular Pacing (MVP) mode in pacemaker patients: Benefit for both sinus node disease (SND) and AV block (AVB) indications. Heart Rhythm. 2005;Abstract AB21-1.
- Ref Heart Rhythm, Vol. 2, No 11, November 2005
Specifications
Adapta DR with MVP
| Mechanical | |||||
|---|---|---|---|---|---|
| Model | Size (HxWxD mm) | M (g) | V (cc) | Connector | Radiopaque ID |
| ADDR01 | 44.7x47.9x7.5 | 27.1 | 12.1 | IS-1 BI or UNI | PWB |
| ADDR03 | 46.7x47.9x7.5 | 28.1 | 13.0 | 3.2 mm LP BI, IS-1or UNI | PWB |
| ADDR06 | 50.3x47.9x7.5 | 28.5 | 14.2 | 5 or 6 mm UNI* | PWB |
| ADDRS1 (small) | 44.7x42.9x7.5 | 23.6 | 11.1 | IS-1 BI or UNI | PWB |
| ADDRL1 (longevity) | 45.4x52.3x7.5 | 31.3 | 13.1 | IS-1 BI or UNI | PWB |
| Battery | |
|---|---|
| Type | Lithium-iodine |
| Voltage | 2.8 V |
| Average Projected Capacity | |
| Model ADDR01/03/06 | 1.2 Ah |
| Model ADDRS1 | .83 Ah |
| Model ADDRL1 | 1.4 Ah |
| Longevity | with MVP off | with MVP on |
|---|---|---|
| Model ADDR01/03/06 | 11.3 years** | 12.4 years*** |
| Model ADDRS1 | 8.5 years** | 9.4 years*** |
| Model ADDRL1 | 14.0 years** | 15.4 years*** |
*** MVP Mode ON – 50% atrial pacing and 5% ventricular pacing
Serial number begins with N
Adapta D with MVP
| Mechanical | |||||
|---|---|---|---|---|---|
| Model ID | Size (HxWxD mm) | M (g) | V (cc) | Connector | Radiopaque ID |
| ADD01 | 44.7x47.9x7.5 | 27.1 | 12.1 | IS-1 BI or UNI | PWB |
| Battery | |
|---|---|
| Type | Lithium-iodine |
| Voltage | 2.8 V |
| Average Projected Capacity | 1.2 Ah |
| Longevity | |
|---|---|
| 11.3 years* | 12.4 years** with MVP On |
** MVP Mode ON – 50% atrial pacing and 5% ventricular pacing
Serial number begins with N
Adapta VDD
| Mechanical | |||||
|---|---|---|---|---|---|
| Model | Size (HxWxD mm) | M (g) | V (cc) | Connector | Radiopaque ID |
| ADVDD01 | 44.7x42.9x7.5 | 23.6 | 11.1 | IS-1 BI or UNI | PWB |
| Battery | |
|---|---|
| Type | Lithium-iodine |
| Voltage | 2.8 V |
| Average Projected Capacity | .86 Ah |
| Longevity |
|---|
| 9.0 years* |
Ω pacing impedance
Nominal values indicated in bold
Serial number begins with N
Adapta SR
| Mechanical | |||||
|---|---|---|---|---|---|
| Model | Size (HxWxD mm) | M (g) | V (cc) | Connector | Radiopaque ID |
| ADSR01 | 40.2x42.9x7.5 | 21.5 | 9.7 | IS-1 BI or UNI | PWB |
| ADSR03 | 42.9x42.9x7.5 | 22.5 | 10.5 | 3.2 mm LP BI, IS-1 BI or UNI | PWB |
| ADSR06 | 43.3x42.9x7.5 | 22.5 | 11.0 | 5 or 6 mm UNI* | PWB |
| Battery | |
|---|---|
| Type | Lithium-iodine |
| Voltage | 2.8 V |
| Average Projected Capacity Models ADSR01/03/06 | .86 Ah |
| Longevity | |
|---|---|
| Models ADSR01/03/06 | 10.0 years** |
Serial number begins with N
